Vanguard Group
CERE

Vanguard Group’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Vanguard Group’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-7,154,343
Closed -$293M – 4433
2024
Q2 		$293M Sell
7,154,343
-309,568
-4% -$12.9M 0.01% 1276
2024
Q1 		$315M Buy
7,463,911
+88,941
+1% +$3.74M 0.01% 1261
2023
Q4 		$313M Buy
7,374,970
+1,003,594
+16% +$28.8M 0.01% 1259
2023
Q3 		$139M Buy
6,371,376
+708,826
+13% +$17.7M ﹤0.01% 1631
2023
Q2 		$180M Sell
5,662,550
-464,030
-8% -$14.2M ﹤0.01% 1517
2023
Q1 		$149M Buy
6,126,580
+88,119
+1% +$2.59M ﹤0.01% 1609
2022
Q4 		$190M Buy
6,038,461
+164,460
+3% +$4.64M 0.01% 1463
2022
Q3 		$166M Buy
5,874,001
+861,581
+17% +$25.7M ﹤0.01% 1500
2022
Q2 		$133M Buy
5,012,420
+202,727
+4% +$5.76M ﹤0.01% 1653
2022
Q1 		$168M Buy
4,809,693
+7,856
+0.2% +$229K ﹤0.01% 1652
2021
Q4 		$156M Buy
4,801,837
+108,678
+2% +$3.83M ﹤0.01% 1744
2021
Q3 		$138M Buy
4,693,159
+1,168,443
+33% +$32.8M ﹤0.01% 1800
2021
Q2 		$90.3M Buy
3,524,716
+296,575
+9% +$4.25M ﹤0.01% 2045
2021
Q1 		$44.3M Buy
3,228,141
+82,067
+3% +$1.2M ﹤0.01% 2384
2020
Q4 		$52.2M Buy
+3,146,074
New +$40.9M ﹤0.01% 2178

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Vanguard Group's CERE Position: Q3 2024 in Review

Vanguard Group sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 7,154,343 shares — an estimated $293M sold.

Vanguard Group first reported a position in CERE in Q4 2020 and held it in 15 quarters. The position peaked at $315M in Q1 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Vanguard Group reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Vanguard Group sold 7,154,343 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $293M.
  • Vanguard Group first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 15 quarters.
  • Vanguard Group's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $315M in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Vanguard Group's 13F filing for Q3 2024, filed 13 Nov 2024.